<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504854</url>
  </required_header>
  <id_info>
    <org_study_id>ADC-037-RES</org_study_id>
    <nct_id>NCT01504854</nct_id>
  </id_info>
  <brief_title>Resveratrol for Alzheimer's Disease</brief_title>
  <official_title>Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alzheimer's Disease Cooperative Study (ADCS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol is derived from plants and is found in highest levels in red wine and the skin of
      red grapes. A recent study reported that monthly and weekly consumption of red wine is
      associated with a lower risk of dementia. There is compelling evidence that caloric
      restriction can improve overall health by activating a class of enzymes known as Sirtuins.
      Resveratrol is a substance found in some plants that directly activates sirtuins, mimicking
      the effects of caloric restriction and may affect regulatory pathways of diseases of aging,
      including Alzheimer's disease (AD).

      In this study, people with AD will be given either Resveratrol or placebo for 12 months to
      determine whether daily resveratrol therapy is beneficial in delaying or altering the
      deterioration of memory and daily functioning. Subjects age 50 and above with a diagnosis of
      probable AD may qualify for participation in this study. A small group of 15 participants
      will be asked to take part in a more detailed 24-hour Pharmacokinetic (PK) sub-study that
      will measure resveratrol levels over a 24 hour period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double blind, placebo-controlled trial will be conducted at approximately 26 Alzheimer's
      Disease Cooperative Study (ADCS) clinical centers. One hundred twenty (120) patients with
      mild to moderate dementia due to probable Alzheimer's disease (AD) will be randomly assigned
      to treatment (1:1) with resveratrol starting at 500 mg once daily or matching placebo,
      increasing at 13 week intervals to a maximum of 1 gram twice daily (divided into two 500 mg
      capsules taken orally) taken with or without food. Participants will be treated for 52 weeks,
      and will undergo venous blood draws for biomarker analysis at Baseline and at 52 weeks;
      participants will also undergo two lumbar punctures for biomarker analyses of cerebrospinal
      fluid (CSF) at Baseline and at Week 52. Participants will undergo magnetic resonance imaging
      (MRI) to measure rate of whole-brain and regional atrophy at Screening, Week 13 and Week 52
      visits. Randomization will be stratified by site. For monitoring of potential toxicities of
      the study drug - particularly nephrotoxicity - subjects will undergo physical examination,
      neurological examination, adverse event review, blood chemistries to include blood urea
      nitrogen (BUN) and Creatinine (Cr), pharmacokinetic (PK) analyses for resveratrol and its
      metabolites, and urinalysis every 6-7 weeks during the study. Clinical, Cognitive and
      Functional effects of resveratrol and insulin and glucose metabolism will also be assessed.

      A subgroup of approximately 15 subjects enrolled will be randomized 4:1 (N = 15, 12 treated +
      3 placebo) for more detailed 24-hour PK analysis. For these individuals, blood samples will
      be collected at 15 different time points. Measurements will include levels of resveratrol and
      its major metabolites (sulfated- and glucuronidated-resveratrol). These subjects will
      complete the detailed PK with each dosage step. This 24-hour PK sampling in the subgroup will
      occur after the first dose following Baseline, after the first dose at each dose increment
      (Weeks 13, 26 and 39), and after the final dose (Week 52).

      Enrollment will be restricted to individuals who are able to abstain from ingesting large
      quantities of resveratrol-containing foods (including red wine). 1-2 glasses of red wine or
      red grape juice and 1 serving of red grapes daily is acceptable. Subjects must also be able
      to abstain from ingesting herbal/natural preparations or dietary supplements containing
      resveratrol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Baseline, Weeks 6, 13, 19, 26, 32, 39, 45, and 52</time_frame>
    <description>The safety and tolerability of treatment with resveratrol will be assessed by analysis of adverse events, including symptoms, abnormal findings on physical examinations, standard laboratory tests and PK analysis of resveratrol and its major metabolites. The frequencies of adverse events or laboratory abnormalities between the participants who receive resveratrol and those receiving placebo will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>MRI will be used to assess the effect of treatment on rate of whole brain volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Week 52</time_frame>
    <description>The ADCS-ADL is an activities of daily living inventory developed by the ADCS to assess functional performance in participants with AD. The ADCS-ADL includes some items from traditional basic ADL tests (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as instrumental (complex) activities of daily living (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading). This structured questionnaire is administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype</measure>
    <time_frame>Week 52</time_frame>
    <description>CSF Abeta40</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a matching placebo to be taken with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable AD (NINDS-ADRDA criteria).

          -  Age must be 50 years or older.

          -  Able to ingest oral medications.

          -  Caregiver/Study Partner who has direct contact with the participant more than 2 days
             per week to accompany participant to all visits.

          -  MMSE score between 14 and 26 (inclusive).

          -  Modified Hachinski score of less than or equal to 4.

          -  Able to abstain from ingesting large quantities of resveratrol-containing foods
             (including red wine). 1-2 glasses of red wine or red grape juice daily acceptable; 1
             serving of red grapes daily acceptable.

          -  Able to abstain from ingesting herbal/natural preparations or dietary supplements
             containing resveratrol.

        Exclusion Criteria:

          -  Non-AD dementia.

          -  Probable AD with Down syndrome.

          -  History of clinically significant stroke.

          -  Current evidence or history in past two years of epilepsy, focal brain lesion, head
             injury with loss of consciousness or DSM-IV criteria for any major psychiatric
             disorder including psychosis, major depression, bipolar disorder, alcohol or substance
             abuse.

          -  Sensory impairment that would preclude the participant from participating in or
             cooperating with the protocol.

          -  Use of investigational agent within two months of Screening.

          -  Evidence of any significant clinical disorder or laboratory finding that renders the
             participant unsuitable for receiving an investigational drug including clinically
             significant or unstable hematologic, hepatic, cardiovascular, pulmonary,
             gastrointestinal, endocrine, metabolic, renal or other systemic disease or laboratory
             abnormality.

          -  Active neoplastic disease, history of cancer five years prior to screening, including
             breast cancer (history or skin melanoma or stable prostate cancer are not excluded).

          -  History of seizure within past five years.

          -  Pregnancy or possible pregnancy.

          -  Use of resveratrol containing supplements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond S. Turner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego - Comprehensive Alzheimer's Program</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>N. Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of WA / VA Puget Sound Alzheimer's Disease Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nia.nih.gov/alzheimers</url>
    <description>Alzheimer's Disease Education and Referral (ADEAR) Center. The ADEAR Center is a service of the National Institute on Aging (NIA).</description>
  </link>
  <link>
    <url>http://adcs.org</url>
    <description>Alzheimer's Disease Cooperative Study</description>
  </link>
  <reference>
    <citation>Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6(6):e19881. doi: 10.1371/journal.pone.0019881. Epub 2011 Jun 16. Review.</citation>
    <PMID>21698226</PMID>
  </reference>
  <reference>
    <citation>Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: 10.1002/mnfr.201100143. Epub 2011 Jun 20. Review.</citation>
    <PMID>21688389</PMID>
  </reference>
  <reference>
    <citation>Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011 Jan;1215:161-9. doi: 10.1111/j.1749-6632.2010.05853.x. Review.</citation>
    <PMID>21261655</PMID>
  </reference>
  <reference>
    <citation>Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov 2;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002.</citation>
    <PMID>22055504</PMID>
  </reference>
  <reference>
    <citation>Albani D, Polito L, Forloni G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis. 2010;19(1):11-26. doi: 10.3233/JAD-2010-1215. Review.</citation>
    <PMID>20061622</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>January 28, 2016</results_first_submitted>
  <results_first_submitted_qc>May 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2016</results_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Brain diseases</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Memory problems</keyword>
  <keyword>Mental disorders</keyword>
  <keyword>Cognitive disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A multicenter, double-blind, placebo-controlled trial was conducted June 2012–March 2014 with participants recruited from 26 US academic clinics affiliated with the Alzheimer’s Disease Cooperative Study (ADCS).</recruitment_details>
      <pre_assignment_details>119 subjects were recruited rather than 120.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Resveratrol</title>
          <description>Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Resveratrol</title>
          <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="7.7"/>
                    <measurement group_id="B2" value="73" spread="8.2"/>
                    <measurement group_id="B3" value="71.4" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Cerebrospinal Fluid Amyloid β40 Concentration at 52 Weeks</title>
        <description>Mean change from baseline in cerebrospinal fluid amyloid β40 concentration at 52 weeks</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Post-hoc modified intention-to-treat (ITT) re-analysis of primary outcomes at Week 52 adjusting for age and AD duration in the mixed-model repeated measures model</population>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cerebrospinal Fluid Amyloid β40 Concentration at 52 Weeks</title>
          <description>Mean change from baseline in cerebrospinal fluid amyloid β40 concentration at 52 weeks</description>
          <population>Post-hoc modified intention-to-treat (ITT) re-analysis of primary outcomes at Week 52 adjusting for age and AD duration in the mixed-model repeated measures model</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6456" spread="2282"/>
                    <measurement group_id="O2" value="5622" spread="1736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>The safety and tolerability of treatment with resveratrol will be assessed by analysis of adverse events, including symptoms, abnormal findings on physical examinations, standard laboratory tests and PK analysis of resveratrol and its major metabolites. The frequencies of adverse events or laboratory abnormalities between the participants who receive resveratrol and those receiving placebo will be compared.</description>
        <time_frame>Baseline, Weeks 6, 13, 19, 26, 32, 39, 45, and 52</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>The safety and tolerability of treatment with resveratrol will be assessed by analysis of adverse events, including symptoms, abnormal findings on physical examinations, standard laboratory tests and PK analysis of resveratrol and its major metabolites. The frequencies of adverse events or laboratory abnormalities between the participants who receive resveratrol and those receiving placebo will be compared.</description>
          <population>ITT population</population>
          <units>number of AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)</title>
        <description>MRI will be used to assess the effect of treatment on rate of whole brain volume</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)</title>
          <description>MRI will be used to assess the effect of treatment on rate of whole brain volume</description>
          <population>ITT population</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="12"/>
                    <measurement group_id="O2" value="10" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
        <description>The ADCS-ADL is an activities of daily living inventory developed by the ADCS to assess functional performance in participants with AD. The ADCS-ADL includes some items from traditional basic ADL tests (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as instrumental (complex) activities of daily living (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading). This structured questionnaire is administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment.</description>
        <time_frame>Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
          <description>The ADCS-ADL is an activities of daily living inventory developed by the ADCS to assess functional performance in participants with AD. The ADCS-ADL includes some items from traditional basic ADL tests (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as instrumental (complex) activities of daily living (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading). This structured questionnaire is administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="11.6"/>
                    <measurement group_id="O2" value="9.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype</title>
        <description>CSF Abeta40</description>
        <time_frame>Week 52</time_frame>
        <population>ITT analyses. Total population and subpopulation of ApoE4 non-carriers.</population>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype</title>
          <description>CSF Abeta40</description>
          <population>ITT analyses. Total population and subpopulation of ApoE4 non-carriers.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Population</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6574" spread="2346"/>
                    <measurement group_id="O2" value="6560" spread="2190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoE4 non-carriers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5859" spread="2085"/>
                    <measurement group_id="O2" value="6339" spread="1709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over a 52 week period (the duration of the subject's participation in the study).</time_frame>
      <desc>Participants received physical and neurologic examinations and vital signs at each visit. Site investigators classified AEs by severity and causality. If a participant withdrew, an early termination visit similar to a baseline visit was scheduled. An independent Data and Safety Monitoring Board reviewed data quarterly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Resveratrol</title>
          <description>60 subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
Resveratrol: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>60 subjects will receive a matching placebo to be taken with or without food.
Placebo: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Syncope/atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Perforated viscus with perforated sigmoid diverticulitis with peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hiatal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Left femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Complications from colostomy reversal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Low hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Water intoxication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanoma of the lung, Stage 4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Large pleural effusion secondary to stage 4 melanoma of the lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bladder tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malignant glioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Unresponsiveness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Altered mental state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Altered mental state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty breathing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>&quot;Blood clots&quot; in the lung/pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Right peripheral vascular disease (status post Carotid Endarterectomy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="64"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Rafii, MD, PhD</name_or_title>
      <organization>Alzheimer's Disease Cooperative Study</organization>
      <phone>858-846-1300</phone>
      <email>mrafii@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

